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Background/aim: To develop the first Turkish version of the National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI) questionnaire and to investigate its validity and reliability in men with chronic prostatitis/chronic pelvic pain syndrome (CP/
CPPS) and healthy controls.
Material and methods: A total of 204 patients, 116 CP/CPPS and a control group which consisted of 88 healthy individuals were
included in this prospective study. The NIH-CPSI form was first translated into Turkish and later on back into English. Using the
Turkish version of the NIH CPSI, 40 patients completed the same questionnaires twice at 2-week intervals for test-retest concordance.
To evaluate internal consistency and test-retest reliability, Cronbach’s alpha value, and the Spearman correlation test were utilized
respectively.
Results: Our findings demonstrated statistically significant differences in NIH-CPSI scores between the patients and control groups
(P <0.001). Cronbach’s alpha coefficient value of NIH-CPSI was 0.864. Reliability of test-retest was 0.909 (P <0.001). Additionally, the
Spearman correlation test showed that the results obtained using the Turkish NIH-CPSI were significantly correlated.
Conclusion: The first Turkish version of the NIH-CPSI was found to be a reliable and valid instrument for Turkish patients with chronic
prostatitis in both clinical and research settings.
Key words: National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), chronicprostatitis/chronicpelvicpainsyndrome
(CP/ CPPS), Turkish validation

1. Introduction
Despite the higher prevalence of benign prostate
ichyperplasia (BPH) and prostate cancer in men older
than 50 years; prostatitis is the most frequently diagnosed
urological problem in men younger than 50 years and
the third most common urologic diagnosis again in cases
with an age value of >50 years [1]. Chronic prostatitis/
chronic pelvic pain syndrome (CP/CPPS) is a common
urological disease characterized by the limited response
to conventional management approaches and has a
complicated healing process. [2] Men suffering from
chronic CP/CPPS are the largest population being evaluated
in outpatient clinics. The incidence of the pathology ranges
from 5% to 14.2% [3,4] and relevant research studies have
shown that approximately 16% of men may present with a
prostatitis attack at least once in their lifetime [5].
The National Institutes of Health (NIH) classification
describes four patterns of prostatitis; type 1 acute bacterial

prostatitis, type 2 chronic bacterial prostatitis, type 3
CP/CPPS, and type 4 asymptomatic prostatitis [6]. CP/
CPPS has been defined with pelvic pain noted in at least
three of the previous 6 months with no other underlying
causes detected. Additionally, the NIH subclassifies type
3 as inflammatory chronic pelvic pain syndrome (3a) and
noninflammatory chronic pelvic pain syndrome (IIIb) [5].
CP/CPPS is associated with certain symptoms
including pain (during urination and in the abdomen,
lower back, rectum, and genital area), dysuria, urinary
urgency, perineal discomfort, obstructive or irritative
voiding difficulties, and hematospermia. Pain is the
predominant characteristic symptom of CP/CPPS and
it is not only associated with disturbed quality of life but
also significant sexual dysfunction [7–9]. Diagnosis of the
pathology is usually made based on the symptoms stated
where the duration and persistence of these symptoms
constitute the first step in the evaluation of CP/CPPS. The
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National Institutes of Health Chronic Prostatitis Symptom
Index (NIH-CPSI) is a commonly used tool to diagnose
CP/CPPS, to evaluate the severity of symptoms, and to
provide available rational treatment options.
The form consists of three subscales with a total score
ranging from 0 to 43: pain or discomfort (with a total score
ranging from 0 to 21), urinary symptoms (with a total
score ranging from 0 to 10), and impact on the quality of
life (QOL) (with a total score ranging from 0 to 12 points
[1]. Pain scores of perineal or ejaculatory discomfort ≥8
are good predictors of patients with moderate to severe
CP/CPPS [10]. It has been shown that as the symptoms
get more severe, the scores will also be higher (Figure 1).
The translation and linguistic validation of the NIHCPSI into various languages was made previously in a
successful manner [1,4,11,12]. In the present study, we
mainly aimed to form and validate the Turkish version

Figure 1. NIH Chronic Prostatitis Symptom Index (NIH-CPSI).
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of the NIH-CPSI. In addition, we also investigated
whether the patients’ responses to urinary symptoms were
compatible with the International Prostate Symptom Score
(I-PSS) and Visual Analogue Scale (VAS) evaluations
[13,14].
2. Materials and methods
2.1. Study design
The study included 116 CP/CPPS patients referring to Dr.
Lütfi Kırdar Kartal Training and Research Hospital Urology
Department with recurrent symptoms and no response
to conventional management approaches for at least 6
months and 88 healthy controls. Patients with psychiatric
disorders, cancer history, benign prostatic hyperplasia,
and other severe comorbidities were all excluded from
the study program. All of the participants completed the
Turkish NIH-CPSI by themselves. Additionally, they were
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also asked to complete the IPSS and VAS regarding their
urinary symptoms. To evaluate the test-retest reliability,
40 patients were asked to recomplete the NIH-CPSI once
again two weeks later. The study protocol was approved
by the ethics committee of our hospital, and all the
participants were asked to sign a detailed informed consent
stating all procedures in line with the Helsinki Declaration
(193/2013).
2.2. Translation process
To perform the translation process, the multistep validation
method defined by Hutchinson et al. was used as a guide
[15]. These steps are outlined below:
1. The questionnaire was translated from English to
Turkish by two independent translators with proper skill
and fluency in speaking both English and Turkish.
2. To compare and evaluate the translated Turkish
forms, a meeting was held between the research group and
the two translators.
3. The final form of the questionnaire on which a
consensus has been reached was translated back into
Turkish language by the two translators simultaneously,
regardless of the source of the original questionnaire.
4. Minor inconsistencies were resolved, and the final
form was given during the second meeting between the
translators and the researchers.
5. Finally, in an attempt to determine whether the
final version of the questionnaire was appropriate and
easily understandable, a pilot study was carried out with
the inclusion of 15 symptomatic patients demonstrating
the highest NIH-CPSI symptom scores. This study
demonstrated the final questionnaire to be understandable
and the final updated form was approved without any
changes (Figure 2).
2.3. Statistical analysis
The general characteristics of the participants were
evaluated using descriptive statistics, and the data were
presented as mean ± standard error of mean (SEM). To
assess the psychometric analysis of NIH-CPSI, reliability,
internal consistency, and test-retest reliability were taken
into consideration. Internal consistency was evaluated using
the Cronbach alpha value, while test-retest reliability was
evaluated using the Spearman correlation test. Discriminant
validity was evaluated based on the information obtained
by comparing the results of the patients with those of the
control group. The Mann–Whitney U test was used to
investigate potential differences and similarities between
the groups. All statistical analyses were performed using
SPSS 22.0 (IBM® SPSS® Statistics V22.0, 2013, USA), and P
<0.05 was considered statistically significant.
3. Results
A total of 116 CP/CPPS patients and 88 healthy controls
were included in the study program and the demographic

characteristics of the patients are shown in Table 1. The
mean age of the CP/CPPS and control groups were 38 and
39.4 years, respectively (P = 0.519). The mean duration of
the symptomatic status in CP/CPPS group was 12 months.
There was a significant difference regarding the NIHCPSI (both the overall scale and subscales) scores of both
groups (P < 0.001) (Table 1). The Spearman correlation test
supported the significant correlation of our Turkish NIHCPSI results. Cross-tabulation with correlations between
the VAS, I-PSS, QOL, total NIH-CPSI and its subscales are
demonstrated in Table 2.
The NIH–CPSI pain scores and VAS in the subgroup
patients were found to be highly correlated (0.66).
Moreover, the correlation between voiding scores and IPPS
was found to be highly significant by reaching the value
of 0.01 (r = 0.54) (Table 2). In test-retest evaluation, the
total NIH-CPSI score (0.909) was found to be correlated
well with the scores of the subgroups (P < 0.001). Lastly,
the psychometric analysis has shown a great internal
consistency with high Cronbach’s alfa coefficient values for
the overall NIH-CPSI (0.864) (Table 3).
4. Discussion
Clinical studies using questionnaire forms are a preferred
method in the objective evaluation of subjective complaints.
The NIH-CPSI has been commonly used to evaluate
symptom severity in patients with CP/CPPS. With the
help of this well-prepared questionnaire, urologists have
the chance to understand the past history of the disease
and also to evaluate the response obtained as results of the
treatment applied.
Like all other questionnaires, NIH-CPSI has also
been translated into many languages, and its validation
studies have been performed. To obtain an appropriate,
convenient, and easily understandable form, each
translation should be conducted by qualified, experienced
translators. In our current study we worked with two
independent translators during the four main steps of the
process to prepare the Turkish version of NIH-CPSI from
the original English form following the steps defined by
Hutchinson et al. [15]. In the final stage, we conducted a
pilot study with 15 patients.
Statistical evaluation of our findings demonstrated
well that the Turkish version of the NIH-CPSI had
excellent test-retest reliability (r [15] 0.909) and high
internal consistency (Cronbach’s alpha = 0.864). Internal
consistency was assessed in line with the original studies of
Litwin et al. [1]. In the original questionnaire, nine items
had high test-retest reliability (r: 0.83 to 0.93) and internal
consistency (Cronbach’s alpha: 0.86 to 0.91).
Other validation studies regarding the application of
NIH-CPSI, namely the Italian version (Cronbach’s alpha =
0.84–0.96), the Korean version (Cronbach’s alpha = 0.86–

503

COŞKUN et al. / Turk J Med Sci

Figure 2. Turkish NIH Chronic Prostatitis Symptom Index (NIH-CPSI).

0.97), the Japanese version (Cronbach’s alpha = 0.83–0.87),
the Brazilian version (Cronbach’s alpha = 0.85–0.93), and
the Persian version (Cronbach’s alpha = 0.865) [11,12,16–
18,] showed similar results with high level confirmation of
the internal consistency.
Our study is not the first study regarding the use
of NIH-CPSI or treatment of CP/CPPS in Turkey but
our study is the first study on Turkish validation of
NIH-CPSI. For example, although Arda et al. used the
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UPOINT classification according to NIH-CPSI scores in
the treatment of CP/CPPS patients, no validation of NIHCPSI in Turkish was mentioned in their study [19]. Again
in the study performed by Sönmez et al. in 2011, the sexual
dysfunction of CP/CPPS patients was included and the
NIH-CPSI form was used. However, Turkish validation of
NIH-CPSI was not used in this trial either [20].
Furthermore, despite numerous validation studies
being conducted on NIH-CPSI none of them to date
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Table1. Baseline characteristics: age, duration of symptoms, NIH-CPSI scores, VAS, I-PSS, and QOL
in the study groups.
CP/CPPS

Controls

P*

No. of patients

116

88

Mean age (SEM)

38 (9.3)

39.4 (10.7)

0.519

Duration of symptoms, month (range)

12 (16–240)

Mean score of NIH-CPSI (SEM) Total (0-43)

22.8 (7.7)

2.5 (1.7)

<0.001

Pain (0–21)

9.5 (4.8)

1.4 (1.2)

<0.001

Urinary symptoms (0–10)

6 (3.2)

0.6 (0.8)

<0.001

Life quality impact (0–12)

7.3 (2.3)

0.5 (0.6)

<0.001

VAS (0–10)

4.5 (1.8)

1.2(0.3)

<0.001

I–PSS (0–35)

14.3 (8.5)

7.5(2.6)

<0.001

*The MannpWhitney U-test NIH-CPSI: National Institute of Health Chronic Prostatitis Symptom
Index, VAS: Visual Analog Scale, IPSS: International ProstateSymptomScore, SEM: Standart eror of
mean.
Table 2. Correlation matrix (Spearman) of VAS, I-PSS, QOL, and NIH-CPSI and its subscales among
116 patients with CPPS.
NIH-CPSI
Total

NIH-CPSI
Pain

NIH-CPSI
Void

NIH-CPSI
Qol

VAS

IPSS

NIH-CPSI Total
NIH-CPSI Pain

r = 0.77**

NIH-CPSI Void

r = 0.72**

r = 0.33**

NIH-CPSI Qol

r = 0.66**

r = 0.25*

VAS

r = 0.6**

r = 0.66**

r = 0.22*

r = 0.29**

IPSS

V0.48**

r = 0.24*

r = 0.54**

r = 0.4**

r = 0.42**
r = 0.25*

**Correlation is significant at the 0.01 level.
*Correlation is significant at the 0.05 level
VAS: Visual Analog Scale, NIH-CPSI: National Institute of Health Chronic Prostatitis Symptom
Index, IPSS: International Prostate Symptom Score, Qol: Quality of life.
Table 3. Reliability of the test-retest analysis (Spearman) and internal consistency (Cronbach’s alpha
coefficient) of the present study.
Domain

Cronbach’ salpha

Test

Retest

Correlation

NIH-CPSI total

0.864

22.8 (7.7)

22.5(7.1)

0.909**

Pain

0.862

9.5 (4.8)

9.4 (5.5)

0.886**

Urinarysymptoms

0.819

6 (3.2)

5.7 (2.9)

0.925**

Life quality impact

0.762

7.3 (2.3)

7.4 (2.5)

0.874**

**Correlation is significant at the 0.01 level. NIH-CPSI: National Institute of Health Chronic
Prostatitis Symptom Index.

have focused on the correlation with VAS and IPSS
questionnaires [11,13]. In light of this fact, apart from
being the first Turkish NIH-CPSI validation study, our
study has a distinct position from other studies considering

the excellent correlation between the results of NIH-CPSI
subgroups and also IPSS and VAS questionnaires (PainVAS correlation: 0.66, urinary symptom-IPSS correlation:
0.54).
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Our study had some potential limitations. First, the
socio-cultural characteristics of the patients were variable
and the number of participants in the control group was not
as high as that in the CP/CPPS group. The socio-cultural
differences, such as education and dialects of patients have
also been shown to affect the understandability of the form
[1,3,11]. Secondly, our study was not a multicenter one
which might give further reliable data.
5. Conclusion
In light of our current findings, we believe that the Turkish
version of NIH-CPSI is a simple, feasible, and reliable form
to be used with CP/CPPS patients. However, we believe
that further clinical studies regarding the use of the Turkish
version among Turkish patients need to be conducted in an
attempt to increase the sensitivity of this test. Such studies
will provide valuable relevant data to establish the profile of
Turkish patients with CP/CPPS and also to determine the
prevalence of cases with these symptoms in our country.
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